Kogan Yakov Form 4 June 28, 2012

FORM 4

OMB APPROVAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

Washington, D.C. 20549

January 31, Expires: 2005

SECURITIES Form 4 or

Estimated average burden hours per response... 0.5

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person * 2. Issuer Name and Ticker or Trading Kogan Yakov

(Middle)

Symbol

Issuer

CLEVELAND BIOLABS INC [CBLI]

(Check all applicable)

5. Relationship of Reporting Person(s) to

3. Date of Earliest Transaction (Month/Day/Year)

X Director 10% Owner X_ Officer (give title _ Other (specify below)

6. Individual or Joint/Group Filing(Check

Chief Executive Officer

C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET

(First)

(Street)

4. If Amendment, Date Original

06/26/2012

Applicable Line)

Filed(Month/Day/Year) _X_ Form filed by One Reporting Person Form filed by More than One Reporting

BUFFALO, NY 14203

(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
--------	---------	-------	--

		1 abit	: 1 - MOII-D	ciivative S	ccurn	ies Acq	luii eu, Disposeu (n, or belieficial	ly Owneu
1.Title of Security	2. Transaction Date (Month/Day/Year)		3. Transactio	4. Securities Acquired on(A) or Disposed of			5. Amount of Securities	6. Ownership Form: Direct	7. Nature of Indirect
(Instr. 3)	(======================================	any	Code	(D)		Beneficially	(D) or	Beneficial	
		(Month/Day/Year)	(Instr. 8)	(Instr. 3, 4 and 5)		Owned Following	Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
					(A)		Reported		
			Code V	Amount	or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common stock, par			Code ,	rimount	(D)	11100			
value \$0.005 per share (1) (3)	06/26/2012		A	27,482	A	\$0	671,982	D	

Common

stock, par Held by value 06/26/2012 A 15,665 A \$ 0 17,377 I spouse (2) \$0.005 per

share (2) (3)

Edgar Filing: Kogan Yakov - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 9. Nu Deriv Secur Bene Own Follo Repo Trans

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.		5.	6. Date Exerc	cisable and	7. Titl	le and	8. Price of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transa	ctio	rNumber	Expiration D	ate	Amou	ınt of	Derivative
Security	or Exercise		any	Code		of	(Month/Day/	Year)	Under	rlying	Security
(Instr. 3)	Price of		(Month/Day/Year)	(Instr.	8)	Derivative	e		Secur	ities	(Instr. 5)
	Derivative					Securities			(Instr.	. 3 and 4)	
	Security					Acquired					
	·					(A) or					
						Disposed					
						of (D)					
						(Instr. 3,					
						4, and 5)					
						i, una 5)					
										Amount	
							Date	Expiration		or	
							•	•	Title	Number	
							Exercisable	isable Date		of	
				Code	V	(A) (D)				Shares	

Reporting Owners

	Relationships			
Reporting Owner Name / Address				

Director 10% Owner Officer Other

Chief Executive Officer

Kogan Yakov

C/O CLEVELAND BIOLABS, INC.
73 HIGH STREET

BUFFALO, NY 14203

Signatures

/s/ Leah Brownlee, Attorney-in-fact for Yakov Kogan 06/28/2012

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares of restricted stock were granted to the reporting person under the Equity Incentive Plan, as amended (the "Plan"), of Cleveland BioLabs, Inc. (the "Company").
- Leah Brownlee, who was hired as an employee of the Company effective March 1, 2010, is the spouse of the reporting person. These shares of restricted stock were granted to Ms. Brownlee under the Plan. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, or for any other purpose.
- (3) The recipients have elected to receive these shares of restricted stock in lieu of a portion of their cash salaries. These shares of restricted stock will become fully vested on December 16, 2012, unless the recipient ceases to be an employee or an affiliate of the Company.

Reporting Owners 2

Edgar Filing: Kogan Yakov - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.